The transcapillary extraction of diphosphonate, as [ 99m Tc]EHDP, a substance used in bone scanning and for management of certain metabolic bone diseases, has been examined. The maximum instantaneous extraction for [ 99m Tc]EHDP was 0.27 ± 0.05 (mean ± SD, N = 10) and the net extraction at 5 min was 0.18 ± 0.05 (N = 10). The permeability ratio of [ 99m Tc]EHDP to the freely diffusible compound, sucrose, using the formula PS = − F s log e (1 − E max ), was 0.71. This is similar to the ratio of diffusion coefficients of EHDP to sucrose, which is estimated to be 0.78. These results suggest that the mechanism by which [ 99m Tc]EHDP passes through the capillaries in bone is passive diffusion. Tissue level estimations of EHDP confirm a rapid blood clearance associated with an increase in the rate of urinary excretion; the level of [ 99m Tc]EHDP in bone, however, remains constant. The fractional excretion of [ 99m Tc]EHDP was 27.3 ± 2.0% in control dogs and was unchanged by thyroparathyroidectomy and subsequent infusion of parathyroid hormone.
KeywordsEHDP; capillary extraction; diffusion; bone capillary permeability; indicator-dilution technique; renal clearance; parathyroid hormone; bone scanning; technetium-labeled phosphate compounds; tracer exchange; tissue uptake; blood flow Bone scanning with radioactive isotopes is used with increasing frequency in clinical practice, particularly to detect metastases in bone before they are visible on radiographs (15), to diagnose infections involving bone or joints (2), and to study rates of union of fractures (33).Until recently, the isotopes available for bone scanning included strontium-85 and -87m, and fluorine-18. However, in 1971, Subramanian et al. (31) labeled a polyphosphate with technetium-99m and introduced the phosphate compounds as bone scanning agents. Of the phosphate compounds currently available, technetium-labeled ethane-l-hydroxy-1,1-diphosphonate ([ 99m Tc]-EHDP) appears to be the best (16).EHDP is synthesized from acetic acid and phosphorus trichloride and is injected, labeled with technetium, as a stannous salt. It is stable in vivo and binds by chemi-sorption onto the (18). In therapeutic doses, it inhibits crystal growth, and in patients with osteoporosis large doses of EHDP lead to osteoid formation and to vitamin Ddeficiency rickets (17). Currently, EHDP is being used in the treatment of Paget's disease of bone (27). To reach the hydroxyapatite crystal, [ 99m Tc]EHDP is transported through the capillaries that lie within the Haversian system of the cortex of bone. We have examined the exchange of [ 99m Tc]EHDP across the capillaries in bone, using the indicator-dilution technique. We have also investigated the uptake by the tissues of [ 99m Tc]EHDP, its excretion by the kidneys, and the effect of parathyroid hormone on its renal clearance.
Materials and Methods
Extraction and permeabilityTen adult male dogs were anesthetized and the nutrient artery of the tibia was approached by the transfibular route. The nutrient artery was cannulated wit...